Vivos Therapeutics. v. Ortho-Tain

142 F.4th 1262
CourtCourt of Appeals for the Tenth Circuit
DecidedJuly 8, 2025
Docket24-1061
StatusPublished
Cited by2 cases

This text of 142 F.4th 1262 (Vivos Therapeutics. v. Ortho-Tain) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Vivos Therapeutics. v. Ortho-Tain, 142 F.4th 1262 (10th Cir. 2025).

Opinion

Appellate Case: 24-1061 Document: 71-1 Date Filed: 07/08/2025 Page: 1 FILED United States Court of Appeals PUBLISH Tenth Circuit

UNITED STATES COURT OF APPEALS July 8, 2025

Christopher M. Wolpert FOR THE TENTH CIRCUIT Clerk of Court _________________________________

VIVOS THERAPEUTICS, INC.,

Plaintiff - Appellee,

v. No. 24-1061

ORTHO-TAIN, INC.,

Defendant - Appellant. _________________________________

Appeal from the United States District Court for the District of Colorado (D.C. No. 1:20-CV-01634-WJM-JPO) _________________________________

Nathan I. Neff, Neff Law Group PC, Chicago, Illinois, for Defendant-Appellant.

Brenna G. Fisher (Kevin Walton with her on the briefs), Snell & Wilmer LLP, Denver, Colorado, for Plaintiff-Appellee. _________________________________

Before HARTZ, TYMKOVICH, and EID, Circuit Judges. _________________________________

HARTZ, Circuit Judge. _________________________________

On this interlocutory appeal, Ortho-Tain, Inc. challenges, under collateral-

order jurisdiction, the district court’s denial of its motion to dismiss based in part on

absolute litigation immunity and, under pendent appellate jurisdiction, several other

rulings of the court. Following the law of the case established in a prior appeal in this Appellate Case: 24-1061 Document: 71-1 Date Filed: 07/08/2025 Page: 2

matter,1 we conclude that we do not have jurisdiction over the denial of immunity

because it turned on a disputed factual issue. And without appellate jurisdiction to

review that ruling, we cannot exercise pendent jurisdiction over the remaining

interlocutory rulings. Accordingly, we dismiss this appeal for lack of jurisdiction.

I. BACKGROUND

Our prior opinion in this case sets forth the factual background. See Vivos

Therapeutics, Inc. v. Ortho-Tain, Inc., No. 21-1309, 2022 WL 2223141, at *1–2

(10th Cir. June 21, 2022) (Vivos I). We repeat only what is necessary to resolve this

appeal.

Vivos sued Ortho-Tain in the United States District Court for the District of

Colorado after Leslie Stevens, Ortho-Tain’s chief executive officer, and Nathan Neff,

its attorney, sent a series of communications to Benco Dental Supply, accusing Benco

of hosting seminars where Vivos misrepresented Ortho-Tain’s products as Vivos’s

own products. In response to the lawsuit, Ortho-Tain sued Vivos in the United States

District Court for the Northern District of Illinois.

Vivos later filed an amended complaint asserting six claims against Ortho-

Tain: Count I – False Advertising in Violation of the Lanham Act, 15 U.S.C.

§ 1125(a)(1); Count II – Violation of the Colorado Consumer Protection Act, Colo.

Rev. Stat. § 6-1-105; Count III – Libel Per Se; Count IV – Slander Per Se; Count V –

1 Later footnotes in this opinion, however, express our doubts about the present validity of two of the statements of law in our prior unpublished opinion. 2 Appellate Case: 24-1061 Document: 71-1 Date Filed: 07/08/2025 Page: 3

Intentional Interference with Contractual Relations; and Count VI – Declaratory

Judgment that Vivos Did Not Violate the Lanham Act.

Ortho-Tain moved to dismiss the amended complaint. Among other things, it

argued that Counts III, IV, and V should be dismissed because the communications

underlying those claims were preliminary to and related to the Illinois litigation and

therefore protected by the Colorado litigation privilege.

When the district court denied the motion, Ortho-Tain appealed. We held that

we lacked jurisdiction over the denial of immunity for Neff’s communications

because that denial turned in part on disputed factual questions. We did, however,

assert jurisdiction over the denial of immunity for Stevens’s communications, which

had been based on the purely legal ground that nonattorneys could not invoke the

privilege. We held that the privilege can apply to nonattorneys and that the district

court should have reviewed Stevens’s and Neff’s statements together to see whether

their statements, as a whole, related to the Illinois litigation and whether that

litigation was contemplated in good faith. We declined to exercise pendent

jurisdiction over Ortho-Tain’s appeal of the other interlocutory rulings.

On remand the district court again denied Ortho-Tain’s motion to dismiss. See

Vivos Therapeutics, Inc. v. Ortho-Tain, Inc., No. 20-cv-1634-WJM-JPO, 2024 WL

625704, at *1 (D. Colo. Feb. 14, 2024). Regarding the immunity issue, it explained

that it would not “delve into the factfinding endeavor of whether the communications

in spring of 2020 were made in good faith contemplation of litigation.” Id. at *3.

3 Appellate Case: 24-1061 Document: 71-1 Date Filed: 07/08/2025 Page: 4

Ortho-Tain appealed again. Vivos has moved to dismiss the appeal for lack of

jurisdiction.

II. DISCUSSION

A. Law of the Case

As we stated in the opening paragraph of this opinion, the outcome of this

appeal is determined by the law-of-the-case doctrine. “Under this doctrine, the

decision of the appellate court establishes the law of the case and ordinarily will be

followed by both the trial court on remand and the appellate court in any subsequent

appeal.” Cressman v. Thompson, 798 F.3d 938, 946 (10th Cir. 2015) (internal

quotation marks omitted). “We will only deviate from the law of the case (1) when

the evidence in a subsequent trial is substantially different; (2) when controlling

authority has subsequently made a contrary decision of the law applicable to such

issues; or (3) when the decision was clearly erroneous and would work a manifest

injustice.” Id. (internal quotation marks omitted). We will have occasion to address

exceptions (2) and (3) in footnote 3.

B. Appellate Jurisdiction Over Immunity Claim

1. The Litigation Privilege

Before addressing appellate jurisdiction, we must say a few words about the

litigation privilege. Neither party disputes that we review the claim of privilege under

Colorado law. Colorado has adopted the “formulation of the [litigation] privilege in

[§ 586 of] the Restatement (Second) of Torts.” Killmer, Lane & Newman, LLP v.

BKP, Inc., 535 P.3d 91, 96 (Colo. 2023) (internal quotation marks omitted). Section

4 Appellate Case: 24-1061 Document: 71-1 Date Filed: 07/08/2025 Page: 5

586 provides that “[a]n attorney at law is absolutely privileged to publish defamatory

matter concerning another in communications preliminary to a proposed judicial

proceeding, or in the institution of, or during the course and as a part of, a judicial

proceeding in which he participates as counsel.” Id. (internal quotation marks

omitted).

The Colorado Court of Appeals has set forth the following elements for the

privilege to apply: “(1) the statement must have some relation to the subject matter of

the litigation; (2) the statement must be made in furtherance of the objective of the

litigation; and (3) in the case of prelitigation statements, the proceedings must

actually be contemplated in good faith.” Coomer v. Donald J. Trump for President,

Inc., 552 P.3d 562, 598 (Colo. App. 2024). Elaborating on the third element, the

Colorado Supreme Court has said that the privilege applies to “pre-litigation

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
142 F.4th 1262, Counsel Stack Legal Research, https://law.counselstack.com/opinion/vivos-therapeutics-v-ortho-tain-ca10-2025.